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de Tecnologı́a Agropecuaria, Hurlingham, Argentina, 2 Laboratorio de Fisiopatogenia, Departamento de
Fisiologı́a, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina, 3 Laboratorio de
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Abstract
Ruminants are the primary reservoir of Shiga-toxin producing Escherichia coli (STEC)
O157:H7 and the main source of infection for humans. The aim of this study was to assess
the immunogenic properties of a candidate vaccine consisting on the recombinant proteins
of E. coli O157:H7 IntiminC280, the carboxy-terminal fraction of Intimin γ, EspB and the
fusion protein between the B subunit of Stx2 and Brucella Lumazine Synthase (BLS)(BLS-
Stx2B), in Holstein Fresian calves.To accomplish this goal we vaccinated calves with two
doses of different vaccine formulations: 2 antigens (IntiminC280, EspB), 3 antigens (Inti-
minC280, EspB, BLS-Stx2B), BLS-Stx2B alone and a control non-vaccinated group. All anti-
gens were expressed as recombinant proteins in E. coli. Specific IgG titres increased in
vaccinated calves and the inclusion of BLS-Stx2B in the formulation seems to have a stimu-
latory effect on the humoral response to IntiminC280 and EspB after the booster. The neu-
tralizing activity of antibodies against these two antigens was assessed in Red Blood Cell
lysis assays and adherence to Hep-2 cells as a correlate of T3SS activity. Both sera from
animals vaccinated with 2 or 3 antigens inhibited both virulence properties. Serological
response to Stx2 was observed in animals vaccinated only with BLS-Stx2B and with 3 anti-
gens and neutralization of Stx2 cytotoxicity was also observed in both groups. In conclusion,
immunization of calves with BLS-Stx2B, IntiminC280 and EspB elicited a potent humoral
response able to neutralize Shiga toxin 2 cytotoxity and the T3SS virulence properties in
vitro. These results suggest that this formulation is a good candidate vaccine to reduce
STEC shedding in cattle and needs to be further assessed in vivo.
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Introduction
Enterohemorragic Escherichia coli (EHEC) O157:H7 is a major etiologic agent of diseases in
humans, whose clinical spectrum includes diarrhoea, haemorrhagic colitis and haemolytic ure-
mic syndrome (HUS), the leading cause of chronic renal failure in children in Argentina and
several other countries[1, 2].
Cattle are the main reservoir of EHEC O157:H7, which predominately colonizes the lym-
phoid follicle-dense mucosa at the terminal rectum and the rectoanal junction (RAJ)[3].
E. coli O157:H7 is characterized by several virulence-associated traits which enables it to
colonize the intestinal mucosa of humans and animals with a characteristic histopathological
lesion known as “attaching and effacing” (A/E). A large chromosomal pathogenicity island
called Locus of Enterocyte Effacement (LEE) is associated with A/E activity [4–6]. The LEE
encodes a type three secretion system (TTSS) that translocates effector proteins responsible for
the A/E lesion into the host cell. Tir, EspB and other LEE-encoded and non-LEE encoded
effectors are translocated into the host cell through a transiently produced filamentous struc-
ture [7], which consists of an assembly of EspA subunits [8] and contributes, in turn, to the
creation of a pore in the eukaryotic cell membrane. Intimin, a bacterial outer membrane pro-
tein, binds to Tir, the translocated Intimin receptor in the host cell membrane, and this bind-
ing leads to the formation of the A/E lesion.
This bacterium also produces Shiga toxins types 1 and/or 2 [9–11], which are responsible
for systemic damage in humans. In cattle, a partial suppression of the mucosal immune
response by Shiga toxin has been observed, apparently favouring the intestinal colonization by
E. coli O157:H7 [12–18].
Many virulence factors of E. coli O157: H7 induce an immune response during the course of
natural or experimental infections in animals and in patients with HUS. Oral inoculation of
calves and steers with E. coli O157: H7 promotes an increase in serum antibody titres against
O157 lipopolysaccharide and neutralizing antibodies to Shiga toxins [19]. Furthermore, Bretsch-
neider et al [20] demonstrated that cattle respond serologically to Intimin and EspB of E. coli
O157:H7 during the course of experimental infection. Antibodies against these proteins have
also been detected in colostra and milk from cows [21–23]
Several authors have reported that calves and adult cattle shed fewer bacteria after several
experimental inoculations, which could be related to a partially protective immune response
elicited by previous infection [24–27]. Our group has demonstrated that naturally acquired
antibodies against IntiminC280 can reduce shedding in experimentally challenged calves, sug-
gesting a protective role for antibodies [27, 28].Vaccination of cattle with bacterial colonization
factors has been suggested as a strategy to prevent E. coli O157:H7 infection. Various vaccine
formulations have been assayed with variable results [29–34]. We, along with other groups,
have demonstrated that vaccination of calves with type three secretion injection apparatus pro-
teins results in reduced excretion of EHEC O157:H7 after experimental infection with an oral
challenge dose of 1010 CFU [29, 32–35]. Despite the reduced shedding observed, protection
was not complete and thus, the current vaccination strategy is ought to be optimized.
As mentioned above, Stx might act as an immunomodulating agent during STEC infections
in cattle and is a virulence factor harboured by all STEC strains, which makes them interesting
vaccine candidates [36]. Considering that Stx2 is the most pathogenic Stx toxin[37], we chose
a Stx2B-based immunogen to raise antibodies against Stx2. Taking into account that its B sub-
unit is a very poor immunogen[38], a novel antigen which comprises the B subunit of Stx2
fused to the N-terminus of Brucella Lumazine Synthase (BLS) was used [39]. This highly stable
BLS-Stx2B fusion protein was able to induce a significant response in mice [40] and therefore
we tested this immunogen in cattle.
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In consequence, the aim of this study was to assess the immunogenic properties of BLS-
Stx2B, and the effect of the inclusion of this antigen on the response to IntiminC280 and EspB,




Eighteen four-month-old conventionally reared Holstein Friesian male calves were obtained
from a dairy farm in Buenos Aires Province, Argentina and housed at the Instituto Nacional de
Tecnologı́a Agropecuaria (INTA) research centre. Animals were selected on the basis of absence
of E. coli O157:H7 by enrichment of rectoanal mucosal swabs followed by immunomagnetic sep-
aration following manufacturer‘s instructions (Dynabeads anti-E.coli O157, Invitrogen Dynal
AS, Oslo, Norway), and low levels of serum specific antibodies against IntiminC280 and EspB.
Calves were fed alfalfa pellets, with free access to hay and water and treated prophylactically
upon arrival with 1% ivermectin to control intestinal nematodes. All animal experiments were
performed with the approval of the Institutional Animal Care and Use of Experimentation
Animals Committee (CICUAE) of the National Institution of Agricultural Reserach.
Production of recombinant E. coli O157:H7 proteins
The coding sequence of EspB and IntiminC280 from the bovine E. coli O157:H7 strain 146N
were cloned in pRSET-A vector (Invitrogen Corp., Carlsbad, CA) and expressed in E. coli
BL21 (D3)/pLysS, as described previously [29]. Briefly, the amino terminal-His-tagged pro-
teins were purified from the lysates by affinity chromatography on Nickel-agarose columns
(ProBond nickel-chelating resin; Invitrogen Corp.), eluted under denaturing conditions and
dialyzed against PBS at pH7.4.
The B subunit of Shiga toxin 2 was cloned upstream to the Brucella Lumazine Synthase
(BLS) gene and the recombinant protein was expressed as described elsewhere [39]. This anti-
gen was kindly provided by Fernando Goldbaum from Fundación Instituto Leloir.
Immunization protocol
Calves were randomly separated into four groups and vaccinated according to the following
scheme: non-vaccinated control (n = 4): PBS; Group 3Ag (n = 6): IntiminC280 + EspB + BLS-
Stx2B; Group 2Ag (n = 6): IntiminC280 + EspB; Group Stx (n = 2): BLS-Stx2B. The immunization
protocol consisted on two doses 15 days apart, with 100 μg of each antigen by intramuscular ro-
ute. The antigens were diluted in 1 mL of PBS and emulsified in 1 mL of mineral oil-based adju-
vant (Montanide ISA206, Seppic, France). The control group was vaccinated only with PBS emul-
sified in the adjuvant.
Sample collection
Blood samples were collected from all animals at days 0, 9, 15 and 23 day post vaccination.
Sera was separated by centrifugation at 5000 rpm for 10 min and stored at -20˚C until it was
used.
Antibody response
All sera samples taken before and during the experiment were analysed by ELISA to detect spe-
cific antibodies against the antigens used in the immunization protocol, as described elsewhere
[27, 39]. Briefly, 96-well Nunc-Immuno MaxiSorp assay plates (Nunc, Roskilde, Denmark)
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were coated overnight at 4˚C with 100 μL of either IntiminC280 or EspB at 1 μg/mL in carbon-
ate buffer pH 9.6 or 100 μL of Stx2B at 5 μg/mL. The latter consisted of the B subunit with a
small fragment of the A subunit of Stx2 [39].
After three washes with PBS pH 7.4 containing 0.05% Tween 20 (PBST), non-specific
binding sites were blocked with 3% skimmed milk in PBS for 1 hour at 37˚C. After that,
washes were repeated and serial two-fold dilutions of sera in PBS-T were added (100 μL/
well), starting from 1/50 to assess antibodies against IntiminC280 and EspB. Plates were
incubated for 2h at 37˚C. For each plate, two wells were incubated with PBS-T alone (neg-
ative control), and a known positive sample was included. Each sample was analyzed in
duplicate. After washing with PBS-T, wells were incubated for another hour with 100 μL
of rabbit anti-bovine IgG1 or IgG2 conjugated with horseradish peroxidase (Bethyl Labo-
ratories, Montgomery, USA), at dilutions of 1:10000 in PBS-T. Plates were washed three
times with PBS-T. Finally, ABTS [2,2-azino-di (3-ethyl-benzthiazoline sulphonic acid)]
(Amresco, Solon, USA) in citrate-phosphate buffer pH 4.2 plus 0.01% H2O2 (100μL/well)
was added. Reactions were stopped after 10 min with 100 μL/well of 5% SDS and read at
405nm (OD405) in a BioTekELx808 microplate reader (BioTek Instruments, Winooski,
USA). The antibody titre was expressed as the reciprocal of the end-point dilution result-
ing in an OD405 above the cut-off value. The cut-off value was calculated as the average
plus three times the standard deviation of a negative control without serum. Plates coated
with Stx2B were incubated with sera diluted 1/50 and the colour reaction was developed
using OPD (o-phenylenediamine dihydrochloride). Antibodies against the B subunit of
Shiga toxin 2 were expressed as OD 492.
Functional assays
Inhibition of bovine red blood cell lysis. For this assay the E. coli O157:H7 438/99 strain
was used. This strain was isolated from a healthy cow from a dairy farm in Buenos Aires,
Argentina and is spontaneously resistantto nalidixic acid. It possesses the genes for enterohe-
molysin, γ-intimin, EspA, EspB, Stx2, and the pO157 plasmid.
Briefy, E. coli O157:H7 438/99 was grown in LB broth overnight at 37˚C without shaking.
OD600 was taken to measure the number of bacteria, and then diluted 1:100 into Dulbecco’s
modified Eagle medium (DMEM) lacking phenol red (Gibco-BRL). 2 mL of bacteria was
mixed with pooled sera from each immunization group (inactivated 30 min at 56˚C) to achieve
a 1:20 dilution, into 12-well plates. The plates were incubated for 1 h under a 5% CO2 atmo-
sphere to allow the interaction between specific antibodies and bacteria. Samples were ana-
lysed in duplicate and a positive control without sera was included.
In turn, red blood cells (RBCs) were separated by centrifugation from fresh defibrinated
sheep blood, which was obtained by jugular vein punction, washed three times with 10 mM
PBS (pH 7.4) and resuspended at 5% in PBS. Then, 2 ml of the 5% suspension of RBC in PBS
was added to the plates and incubated for 4 h at 37˚C under a 5% CO2 atmosphere. The sus-
pension was removed from the wells and centrifuged at 12,000×g for 1 min. Supernatants were
monitored for the presence of released haemoglobin by measuring the OD at 543 nm.
OD543 obtained from the positive control, consisting on E. coli O157:H7 strain 438/99 with
no sera, was considered as 100% haemolysis and inhibition of haemolysis was expressed as
100% -% haemolysis of each treatment.
Inhibition of E. coli O157:H7 adherence to Hep-2 cells. 12-well plates were inoculated
with 2,5 X 105 cells per well of HEp-2 (ATCC-CCL-23) and grown to 60–70% confluence at
37˚C in 5% CO2, in DMEM with 10% heat-inactivated foetal bovine serum, 2mM L-gluta-
mine, penicillin (100,000 IU/liter), and streptomycin (100 mg/liter).
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E. coli O157:H7 438/99 was grown in Brain Heart Infusion broth (BHI) with NaHCO3
44mM overnight at 37˚C without shaking. 20 μl of the overnight culture were added to 300 μl
of adherence media (DMEM, mannose 1%, NaHCO3 0.4%) containing pooled sera from each
immunization group (inactivated 30 min at 56˚C) at 1:50 dilution. A positive control without
sera was also included. The mixture was incubated at 37˚C for 30 min to allow the interaction
between E. coli O157:H7 and the antibodies.
Hep-2 cells were washed three times with adherence media, replenished with the mixture of
bacteria and sera (300 ul/well) and incubated at 37˚C in 5% CO2 for three hours. After that,
the cells were washed twice with PBS and replenished with DMEM plus the corresponding
sera diluted 1:50. After two more hours of incubation, the infected monolayers were washed
three times with PBS and the adherent bacteria were recovered with 1 mL of 0.1% Triton X100
in PBS buffer. Dilutions were plated on Sorbitol McConkey agar plates.
The number of recovered bacteria from the positive control (without sera) was considered
as 100% of adherence.
Inhibition of Stx2 cytotoxicity on vero cells. For the neutralization assay, Stx2 (Phoenix
Laboratory, Boston, MA, USA) diluted in Minimum Essential Medium (MEM; Gibco; Life
Technologies Corp., Carlsbad, CA) at a concentration able to inhibit cell viability by 50% was
incubated with several dilutions of pooled sera from the different immunization groups for 1 h
at 37˚C with shaking. These mixes were then assayed in Vero cell culture by using the neutral
red assay adapted from a previously described protocol[41]. Briefly, Vero cells were plated in
96-well plates and grown to confluence in complete MEM medium. Then, cells were incubated
under growth-arrested conditions either with Stx2 alone or with the sera for 72 h and the neu-
tral red uptake was determined. Results are expressed as percentage of cell viability and 100%
represents cells incubated under identical conditions but without the toxoid treatment.
Data analysis
Data are presented as mean ± SEM of three independent experiments. Plotting and statistical
analysis of data was accomplished using GraphPad Prism 5.0 (GraphPad, USA). For ELISA,
RBC lysis and Hep-2 adherence, statistical analysis was performed using 1-way ANOVA and
the Tukey‘s Multiple Comparison post test.
Comparisons between inhibition of Stx2 cytotoxicity means of different groups was per-
formed using two-way ANOVA. Significance was determined using Tukey‘s Multiple Com-
parison test as a posteriori test. In all cases, statistical significance was set at P< 0.05.
Results
Specific IgG antibody titres increase in calves vaccinated with type three
secretion system antigens and the B subunit of shiga toxin
Overall, similar response patterns were observed against IntiminC280 and EspB although the
titres against the former were higher than those observed for EspB (Fig 1). For both antigens,
IgG2 titres were lower than that of IgG1and the IgG2 response to EspB drops after the booster.
The inclusion of the BLS-Stx2B in the formulation seems to have a significant stimulatory
effect on the IgG1 response to IntiminC280 and EspB, since a significantly higher title against
both antigens was observed in the group of calves vaccinated with the 3 antigens. The IgA titers
to neither of these two antigens significantly increased after vaccination.
The specificity of antibodies was confirmed by Western blot (data not shown).
The serological response against Stx2 was measured by ELISA and Fig 2 shows that the IgG
response to BLS-Stx2B was low after the first dose and increased after the booster in both
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groups that received BLS-Stx2B (Fig 2), being statistically significant on day 23 post vaccina-
tion compared to the preimmune condition. Furthermore, the level of specific antibodies on
day 23 was also significantly higher when the chimera vaccinated groups where compared to
the control No difference was observed between the group vaccinated with three antigens or
with BLS-Stx2B alone.
Fig 1. Immunoglobulin G1 (A,C) and G2 (B,D) responses to IntiminC280 (A, B) and EspB (C,D) in calves vaccinated
with IntiminC280 + EspB + BLS-Stx2B (3Ag); IntiminC280 + EspB (2Ag); BLS-Stx2B and PBS (control) measured by
ELISA at different times post vaccination. Data are shown as titers (as reciprocal of dilutions) ± standard error of the
mean. * Indicates statistical significance (p < 0.05) compared to the control and † indicates statistical significance
compared to the 2Ag group.
doi:10.1371/journal.pone.0169422.g001
Fig 2. Immunoglobulin G responses to Stx2B in calves vaccinated with IntiminC280 + EspB (2Ag);
IntiminC280 + EspB + BLS-Stx2B (3Ag); BLS-Stx2B and PBS (control) measured by ELISA at different times
post vaccination. Data are shown as OD492 ± standard error of the mean. * Indicates statistical significance
(p < 0.05) compared to the control and † indicates statistical significance compared to the preimmune condition.
doi:10.1371/journal.pone.0169422.g002
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Bovine sera from animals vaccinated with BLS-Stx2B neutralize Stx2
cytotoxicity on vero cells
Results of neutralization of cytotoxicity on Vero cells are shown in Fig 3. Sera from animals
vaccinated with 3 antigens as well as sera from calves that received only BLS-Stx2B induced a
significant neutralization of Stx2 cytotoxicity compared to the control group from day 9 post
vaccination. As expected, the neutralization ability of sera from animals vaccinated with 2 anti-
gens was similar to the controls. Furthermore, a statistically significant difference was observed
between both groups immunized with the chimera, being the group vaccinated only with
BLS-Stx2B the one that resulted in higher neutralization. A maximum neutralization of around
100%, was observed in the latter, on 15 and 23 days post vaccination.
Vaccination elicits antibodies able to partially inhibit erythrocyte lysis
induced by the T3SS
To measure the neutralizing activity of antibodies against EspB, RBC lysis was used as a corre-
late of T3SS activity since this protein is a component of the T3SS translocon. Both sera from
animals vaccinated with 2Ag or 3Ag, inhibited RBC lysis by 74% and 73% respectively, com-
pared to 60% of sera from non-vaccinated calves (Fig 4). This difference is statistically signif-
icant (p< 0.05).
Vaccination elicits antibodies able to neutralize adherence of EHEC
O157:H7 to epithelial cells in vitro
Inhibition of E. coli O157:H7 adherence to Hep-2 cells was carried out to measure the neutral-
izing activity of antibodies raised through immunization. Sera from animals vaccinated with
either 2 or 3 antigens significantly reduced EHEC adherence (both P<0.05) compared to sera
from non-vaccinated animals, but no significant difference was observed between sera from
calves vaccinated with either 2 or 3 antigens(Fig 5).
Fig 3. Stx2 cytotoxicity neutralization in Vero cells. Results are expressed as percentage of cell viability and
100% represents cells incubated under identical conditions but without the toxin treatment. Data are shown as
mean ± standard error of the mean of 3 experiments performed in quadruplicate (*P<0.05).
doi:10.1371/journal.pone.0169422.g003
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Discussion
Vaccination is one of the pre-slaughter interventions that can be used to reduce EHEC O157:
H7 occurrence in cattle [42]. In order to prevent intestinal colonization, vaccines need to target
molecules involved in EHEC adherence and for this matter, Type III Secreted proteins are
attractive targets for vaccine development [29, 32, 33].
In this work we have proven that vaccination of 4-month-old Fresian Holstein calves with
IntiminC280, EspB and the fusion protein of Shiga toxin 2 B subunit and Brucella Lumazine
Synthase is able to induce a significant immune response against these antigens. These results
coincide with previous reports from our group, as well as with several other authors who have
used T3SS proteins as antigens [23, 29, 34].
The potential of Intimin as a subunit vaccine was suggested following observations that
antibodies against the carboxy-terminal domain inhibit bacterial adherence [43–46]. Further-
more, Intimin has strong antigenic determinants and it has been shown to be a target of
humoral immune responses in different host species and animal models such as humans [47,
48], cattle [21, 29, 32, 34, 35], rabbits [49], pigs [50] and mice [51]. Antibodies against this pro-
tein have also been described after experimental (Bretschneider et al.[20] as well as natural
infections [21, 27, 52].
On the other hand, a humoral response against EspB has been observed after vaccination,
as mentioned previously, and in cattle after natural [21, 27, 52] as well as experimental infec-
tions [27, 29, 53] and in human patients suffering from HUS [53], although it is less antigenic
than Intimin.
The antibodies obtained through immunization in this trial are able to inhibit several viru-
lence traits of E. coli O157:H7 in vitro, as assessed in different functional assays that are a corre-
late of EHEC virulence. Bovine RBC lysis provoked by the T3SS was significantly neutralized
Fig 4. Inhibition of RBC lysis by sera from calves vaccinated with IntiminC280 + EspB + BLS-Stx2B (3Ag);
IntiminC280 + EspB (2Ag); and PBS (control). Results are represented as % of inhibition of RBC lysis caused by
the strain EHEC 438/99 without sera. Data are shown as mean ± standard error of the mean of 3 experiments
performed. * Indicates statistical significance compared to the control (p < 0.05).
doi:10.1371/journal.pone.0169422.g004
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by the antibodies in sera from animals vaccinated with the combination of two as well as three
antigens. This neutralization is most likely caused by anti EspB antibodies as Intimin should
not be involved in RBC lysis [54]. On the other hand, sera from both group of animals vacci-
nated with IntiminC280 also neutralized E. coli O157:H7 adherence to epithelial cell lines. In
both cases, anti-Intimin and anti-EspB antibodies contribute to the neutralization as both viru-
lence factors are needed for a strong attachment of EHEC to epithelia. No significant differ-
ences were observed between the neutralizing activities of sera from animals vaccinated with
two and three antigens suggesting that anti Stx2B antibodies do not contribute to the inhibi-
tion of RBC lysis nor the neutralization of adherence, as expected.
Despite the low level of anti EspB and anti Intimin antibodies detected in the control group,
some neutralization of adherence as well as RBC lysis was observed in the sera of these calves.
This effect might be explained taking into account that many factors present in bovine serum
can unspecifically inhibit the T3SS, such as lactoferrin [55] or α1-antitrypsin [56], both present
in bovine serum [57].Sera from the animals vaccinated with 3 antigens contained higher titers
of anti Intimin antibodies than animals vaccinated with 2 antigens; however the neutralizing
Fig 5. Inhibition of E. coli O157:H7 adherence to Hep-2 cells by sera from calves vaccinated with
IntiminC280 + EspB + BLS-Stx2B (3Ag); IntiminC280 + EspB (2Ag); and PBS (control). Results are represented
as % of inhibition of adherence respect to strain EHEC 438/99 without sera. Data are shown as mean ± standard
error of the mean of 3 experiments performed (*P<0.05). * Indicates statistical significance compared to the control
(p < 0.05).
doi:10.1371/journal.pone.0169422.g005
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activities of RBC lysis and Hep-2 cells adherence were of similar magnitude. This lack of corre-
lation between the antibody level and neutralizing activity may be explained considering that
other adhesins, not neutralized by anti Intimin antibodies, may be involved in EHEC adher-
ence to epithelial cells [58], and that, at the dilution used in these assays, the anti Intimin anti-
bodies present in sera from calves vaccinated with two antigens saturates all Intimin at the
surface of EHEC.
As regards the immune response elicited against Stx2, we observed a specific humoral
response in both groups vaccinated with BLS-Stx2B. The enzyme Lumazine Synthase from
Brucella spp. (BLS) is a highly immunogenic and stable dimer of pentamers and a scaffold with
enormous plasticity to display foreign antigens on its structure [59], which provides a display
platform for Stx2B, since several studies have shown that its pentameric arrangement is only
marginally stable [60], explaining, at least in part, its lack of immunogenicity when employed
alone.
The magnitude of the IgG response is considerably lower compared to that obtained in
mice with the same BLS-Stx2B chimera [39] or with other heterologous antigens carried by
BLS [61–63]. Several factors might account for this difference such as the species as well as the
amount of recombinant protein per weight of animal. Despite the low level of anti-Stx2B anti-
bodies elicited, they were able to neutralize the cytotoxicity produced by Stx2 on Vero cells.
Furthermore, neutralization was observed at days 9 and 15 after vaccination, even no signifi-
cant increase in DO was observed. Similar results have been previously reported in mice
immunized with this chimera, which were able to survive intravenous challenge with the toxin
despite a low level of anti Stx2B antibodies [39], suggesting that high afinity antibodies might
account for this protection. However, affinity was not assessed on this study.
Higher doses of the chimera must be tested in further studies in order to increase the level
of specific antibodies against Stx2B.
Humoral immune response against Shiga toxins in cattle has also been described in natural
infections. Calves bearing maternal and acquired antibodies against Stx1 and in lesser extent,
Stx2 [64] have been reported, sometimes with high frequency of reacting animals [65]. These
antibodies have also been detected in natural bovine colostra [66] and in cows immunized
with Stx2 [22, 23]. No anti Stx2 response was observed after experimental infection of calves
with E. coli O157:H7 [16, 19, 27, 67].
Furthermore, the inclusion of BLS-Stx2B in the formula induces not only antibodies against
Stx2, but also potentiates the IgG1 response to Intimin and EspB. This effect may be due to
BLS since this protein has a demonstrated adjuvant power [62, 68, 69].
We have previously tested a candidate vaccine consisting on the carboxy-terminal fraction
of Intimin γ and EspB that resulted in reduced fecal shedding of E. coli O157:H7 after chal-
lenge[29]. In order to increase the level of protection conferred by vaccination with these two
antigens, we assayed the immunogenicity of the BLS-Stx2B chimera in cattle and the ability of
the antibodies elicited to neutralize Stx2 cytotoxicity. The results obtained here allow us to
conclude that the chimera is a potent immunogen able to elicit Stx2 neutralizing antibodies in
vitro and to induce a strong activation of the humoral response to Intimin and EspB.
Further studies are required to determine if the antibodies elicited against Stx2 and the fur-
ther stimulation of the response to the previously assayed antigens, provides additional protec-
tion against infection of calves with E. coli O157:H7 than the observed for Intimin and EspB
alone. Also the relevance of T-cell mediated immunity was recently demonstrated suggesting
the existence of unexplored epitopes in Intimin that may provide new clues for a stronger pro-
tective response [67].
These results presented here bring insight into vaccine development to prevent bovine car-
riage of E. coli O157:H7 thus, providing a tool to control a national health issue as HUS.
Calves Immune Response after Vaccination with Escherichia coli O157:H7 Antigens
PLOS ONE | DOI:10.1371/journal.pone.0169422 January 3, 2017 10 / 15
Acknowledgments
MP, CI and AC are CONICET fellows, LM and MPM are recipients of CONICET fellowships
and AA is recipient of a University of Buenos Aires fellowship. We thank Fernando Goldbaum
(Fundación Instituto Leloir) and Linus Spatz (Inmunova) for providing BLS-Stx2B and Pablo
Baldi (School of Pharmacy and Biochemistry, University of Buenos Aires) for critical com-
ments on the manuscript. The authors declare that there is no conflict of interests regarding
the publication of this paper.
Author Contributions
Conceptualization: LM MP EM CI AC.
Data curation: AC.
Formal analysis: LM MP EM CI AA.
Funding acquisition: EM CI AC.
Investigation: MP CI AC.





Validation: LM SG DV AA.
Visualization: LM MM MP CI AC.
Writing – original draft: LM MM MP EM CI AC.
Writing – review & editing: LM MM MP EM CI AC.
References
1. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Interna-
tional Journal of Medical Microbiology. 2005; 295(6–7):405–18. Epub 2005/10/22. doi: 10.1016/j.ijmm.
2005.06.009 PMID: 16238016
2. Repetto HA. Long-term course and mechanisms of progression of renal disease in hemolytic uremic
syndrome. Kidney International Supplement. 2005;(97):S102–6. Epub 2005/07/15. KID9717 [pii] doi:
10.1111/j.1523-1755.2005.09717.x PMID: 16014085
3. Grauke LJ, Kudva IT, Yoon JW, Hunt CW, Williams CJ, Hovde CJ. Gastrointestinal tract location of
Escherichia coli O157:H7 in ruminants. Applied and environmental microbiology. 2002; 68(5):2269–77.
Epub 2002/04/27. PubMed Central PMCID: PMC127545. doi: 10.1128/AEM.68.5.2269-2277.2002
PMID: 11976097
4. McDaniel TK, Jarvis KG, Donnenberg MS, Kaper JB. A genetic locus of enterocyte effacement con-
served among diverse enterobacterial pathogens. Proc Natl Acad Sci U S A. 1995; 92(5):1664–8. Epub
1995/02/28. PubMed Central PMCID: PMC42580. PMID: 7878036
5. Elliott SJ, Wainwright LA, McDaniel TK, Jarvis KG, Deng YK, Lai LC, et al. The complete sequence of
the locus of enterocyte effacement (LEE) from enteropathogenic Escherichia coli E2348/69. Mol Micro-
biol. 1998; 28(1):1–4. Epub 1998/05/21. PMID: 9593291
6. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol. 2004; 2(2):123–40.
Epub 2004/03/26. doi: 10.1038/nrmicro818 PMID: 15040260
7. Nougayrede JP, Fernandes PJ, Donnenberg MS. Adhesion of enteropathogenic Escherichia coli to
host cells. Cell Microbiol. 2003; 5(6):359–72. Epub 2003/06/05. 281 [pii]. PMID: 12780774
Calves Immune Response after Vaccination with Escherichia coli O157:H7 Antigens
PLOS ONE | DOI:10.1371/journal.pone.0169422 January 3, 2017 11 / 15
8. Daniell SJ, Kocsis E, Morris E, Knutton S, Booy FP, Frankel G. 3D structure of EspA filaments from
enteropathogenic Escherichia coli. Mol Microbiol. 2003; 49(2):301–8. Epub 2003/06/28. 3555 [pii].
PMID: 12828630
9. Jackson MP, Neill RJ, O´Brien AD, Holmes RK, Newland JW. Nucleotide sequence analysis and com-
parison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages
form Escherichia coli 933. FEMS Microbiol Lett. 1987; 44:109–14.
10. Tesh VL, O’Brien AD. The pathogenic mechanisms of Shiga toxin and the Shiga-like toxins. Mol Micro-
biol. 1991; 5(8):1817–22. Epub 1991/08/01. PMID: 1766367
11. Karpman D, Connell H, Svensson M, Scheutz F, Alm P, Svanborg C. The role of lipopolysaccharide
and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. Journal of Infectious Dis-
eases. 1997; 175(3):611–20. Epub 1997/03/01. PMID: 9041333
12. Olsen SJ, Miller G, Breuer T, Kennedy M, Higgins C, Walford J, et al. A waterborne outbreak of Escheri-
chia coli O157:H7 infections and hemolytic uremic syndrome: implications for rural water systems.
Emerg Infect Dis. 2002; 8(4):370–5. Epub 2002/04/25. PubMed Central PMCID: PMC2730238. doi: 10.
3201/eid0804.000218 PMID: 11971769
13. Meichtri L, Miliwebsky E, Gioffre A, Chinen I, Baschkier A, Chillemi G, et al. Shiga toxin-producing
Escherichia coli in healthy young beef steers from Argentina: prevalence and virulence properties. Inter-
national Journal of Food Microbiology. 2004; 96(2):189–98. Epub 2004/09/15. S0168160504001734
[pii]. doi: 10.1016/j.ijfoodmicro.2004.03.018 PMID: 15364473
14. Hussein HS, Bollinger LM. Prevalence of Shiga toxin-producing Escherichia coli in beef cattle. J Food
Prot. 2005; 68(10):2224–41. Epub 2005/10/26. PMID: 16245735
15. Menge C, Wieler LH, Schlapp T, Baljer G. Shiga toxin 1 from Escherichia coli blocks activation and pro-
liferation of bovine lymphocyte subpopulations in vitro. Infect Immun. 1999; 67(5):2209–17. PubMed
Central PMCID: PMC115959. PMID: 10225876
16. Hoffman MA, Menge C, Casey TA, Laegreid W, Bosworth BT, Dean-Nystrom EA. Bovine immune
response to shiga-toxigenic Escherichia coli O157:H7. Clin Vaccine Immunol. 2006; 13(12):1322–7.
Epub 2006/10/20. CVI.00205-06 [pii]. doi: 10.1128/CVI.00205-06 PMID: 17050743
17. Menge C, Blessenohl M, Eisenberg T, Stamm I, Baljer G. Bovine ileal intraepithelial lymphocytes repre-
sent target cells for Shiga toxin 1 from Escherichia coli. Infection and Immunity. 2004; 72(4):1896–905.
Epub 2004/03/25. doi: 10.1128/IAI.72.4.1896-1905.2004 PMID: 15039308
18. Robinson CM, Sinclair JF, Smith MJ, O’Brien AD. Shiga toxin of enterohemorrhagic Escherichia coli
type O157:H7 promotes intestinal colonization. Proceedings of the National Academy of Sciences of
the United States of America. 2006; 103(25):9667–72. Epub 2006/06/13. 0602359103 [pii]. doi: 10.
1073/pnas.0602359103 PMID: 16766659
19. Johnson RP, Cray WC Jr., Johnson ST. Serum antibody responses of cattle following experimental
infection with Escherichia coli O157:H7. Infect Immun. 1996; 64(5):1879–83. Epub 1996/05/01.
PubMed Central PMCID: PMC174011. PMID: 8613410
20. Bretschneider G, Berberov EM, Moxley RA. Isotype-specific antibody responses against Escherichia
coli O157:H7 locus of enterocyte effacement proteins in adult beef cattle following experimental infec-
tion. Vet Immunol Immunopathol. 2007; 118(3–4):229–38. Epub 2007/07/10. S0165-2427(07)00190-0
[pii]. doi: 10.1016/j.vetimm.2007.06.005 PMID: 17617472
21. Vilte DA, Larzabal M, Cataldi AA, Mercado EC. Bovine colostrum contains immunoglobulin G antibodies
against intimin, EspA, and EspB and inhibits hemolytic activity mediated by the type three secretion sys-
tem of attaching and effacing Escherichia coli. Clin Vaccine Immunol. 2008; 15(8):1208–13. Epub 2008/
06/20. CVI.00027-08 [pii] PubMed Central PMCID: PMC2519310. doi: 10.1128/CVI.00027-08 PMID:
18562563
22. Rabinovitz BC, Gerhardt E, Tironi Farinati C, Abdala A, Galarza R, Vilte DA, et al. Vaccination of preg-
nant cows with EspA, EspB, gamma-intimin, and Shiga toxin 2 proteins from Escherichia coli O157:H7
induces high levels of specific colostral antibodies that are transferred to newborn calves. J Dairy Sci.
2012; 95(6):3318–26. Epub 2012/05/23. S0022-0302(12)00304-9 [pii]. doi: 10.3168/jds.2011-5093
PMID: 22612965
23. Rabinovitz BC, Vilte DA, Larzabal M, Abdala A, Galarza R, Zotta E, et al. Physiopathological effects of
Escherichia coli O157:H7 inoculation in weaned calves fed with colostrum containing antibodies to
EspB and Intimin. Vaccine. 2014; 32(30):3823–9. doi: 10.1016/j.vaccine.2014.04.073 PMID: 24797699
24. Naylor SW, Flockhart A, Nart P, Smith DG, Huntley J, Gally DL, et al. Shedding of Escherichia coli
O157:H7 in calves is reduced by prior colonization with the homologous strain. Applied and environ-
mental microbiology. 2007; 73(11):3765–7. Epub 2007/04/24. AEM.02670-06 [pii]. PubMed Central
PMCID: PMC1932681. doi: 10.1128/AEM.02670-06 PMID: 17449700
Calves Immune Response after Vaccination with Escherichia coli O157:H7 Antigens
PLOS ONE | DOI:10.1371/journal.pone.0169422 January 3, 2017 12 / 15
25. Cray WC Jr., Moon HW. Experimental infection of calves and adult cattle with Escherichia coli O157:
H7. Applied and environmental microbiology. 1995; 61(4):1586–90. Epub 1995/04/01. PubMed Central
PMCID: PMC167413. PMID: 7747972
26. Sanderson MW, Besser TE, Gay JM, Gay CC, Hancock DD. Fecal Escherichia coli O157:H7 shedding
patterns of orally inoculated calves. Vet Microbiol. 1999; 69(3):199–205. Epub 1999/10/08. S0378-1135
(99)00106-6 [pii]. PMID: 10512044
27. Martorelli L, Hovde CJ, Vilte DA, Albanese A, Zotta E, Ibarra C, et al. Impact of Infection Dose and Pre-
vious Serum Antibodies against the Locus of Enterocyte Effacement Proteins on Escherichia coli O157:
H7 Shedding in Calves following Experimental Infection. Biomed Res Int. 2015; 2015:290679. PubMed
Central PMCID: PMCPMC4475743. doi: 10.1155/2015/290679 PMID: 26167480
28. Basu I, Ferens WA, Stone DM, Hovde CJ. Antiviral activity of shiga toxin requires enzymatic activity and
is associated with increased permeability of the target cells. Infect Immun. 2003; 71(1):327–34. Epub
2002/12/24. PubMed Central PMCID: PMC143405. doi: 10.1128/IAI.71.1.327-334.2003 PMID:
12496182
29. Vilte DA, Larzabal M, Garbaccio S, Gammella M, Rabinovitz BC, Elizondo AM, et al. Reduced faecal
shedding of Escherichia coli O157:H7 in cattle following systemic vaccination with gamma-intimin C(2)
(8)(0) and EspB proteins. Vaccine. 2011; 29(23):3962–8. Epub 2011/04/12. S0264-410X(11)00461-0
[pii]. doi: 10.1016/j.vaccine.2011.03.079 PMID: 21477674
30. Smith DR, Moxley RA, Peterson RE, Klopfenstein TJ, Erickson GE, Clowser SL. A two-dose regimen of
a vaccine against Escherichia coli O157:H7 type III secreted proteins reduced environmental transmis-
sion of the agent in a large-scale commercial beef feedlot clinical trial. Foodborne Pathog Dis. 2008; 5
(5):589–98. Epub 2008/08/07. doi: 10.1089/fpd.2008.0080 PMID: 18681791
31. Dziva F, Vlisidou I, Crepin VF, Wallis TS, Frankel G, Stevens MP. Vaccination of calves with EspA, a
key colonisation factor of Escherichia coli O157:H7, induces antigen-specific humoral responses but
does not confer protection against intestinal colonisation. Vet Microbiol. 2007; 123(1–3):254–61. Epub
2007/03/22. S0378-1135(07)00101-0 [pii]. doi: 10.1016/j.vetmic.2007.02.016 PMID: 17374460
32. McNeilly TN, Mitchell MC, Rosser T, McAteer S, Low JC, Smith DG, et al. Immunization of cattle with a
combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli
O157:H7 following oral challenge. Vaccine. 2010; 28(5):1422–8. Epub 2009/11/12. S0264-410X(09)
01606-5 [pii]. doi: 10.1016/j.vaccine.2009.10.076 PMID: 19903545
33. Potter AA, Klashinsky S, Li Y, Frey E, Townsend H, Rogan D, et al. Decreased shedding of Escherichia
coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine. 2004; 22(3–
4):362–9. Epub 2003/12/13. S0264410X03005905 [pii]. PMID: 14670317
34. van Diemen PM, Dziva F, Abu-Median A, Wallis TS, van den Bosch H, Dougan G, et al. Subunit vac-
cines based on intimin and Efa-1 polypeptides induce humoral immunity in cattle but do not protect
against intestinal colonisation by enterohaemorrhagic Escherichia coli O157:H7 or O26:H. Vet Immunol
Immunopathol. 2007; 116(1–2):47–58. Epub 2007/01/30. S0165-2427(07)00006-2 [pii].PubMed Cen-
tral PMCID: PMC2656997. doi: 10.1016/j.vetimm.2006.12.009 PMID: 17258324
35. Vilte DA, Larzabal M, Mayr UB, Garbaccio S, Gammella M, Rabinovitz BC, et al. A systemic vaccine
based on Escherichia coli O157:H7 bacterial ghosts (BGs) reduces the excretion of E. coli O157:H7 in
calves. Vet Immunol Immunopathol. 2012; 146(2):169–76. Epub 2012/03/31. S0165-2427(12)00075-X
[pii]. doi: 10.1016/j.vetimm.2012.03.002 PMID: 22460171
36. Kerner K, Bridger PS, Kopf G, Frohlich J, Barth S, Willems H, et al. Evaluation of biological safety in
vitro and immunogenicity in vivo of recombinant Escherichia coli Shiga toxoids as candidate vaccines in
cattle. Vet Res. 2015; 46:38. PubMed Central PMCID: PMCPMC4391668. doi: 10.1186/s13567-015-
0175-2 PMID: 25889651
37. Wen SX, Teel LD, Judge NA, O’Brien AD. Genetic toxoids of Shiga toxin types 1 and 2 protect mice
against homologous but not heterologous toxin challenge. Vaccine. 2006; 24(8):1142–8. Epub 2005/
10/04. S0264-410X(05)00927-8 [pii]. doi: 10.1016/j.vaccine.2005.08.094 PMID: 16198455
38. Marcato P, Mulvey G, Read RJ, Vander Helm K, Nation PN, Armstrong GD. Immunoprophylactic poten-
tial of cloned Shiga toxin 2 B subunit. Journal of Infectious Diseases. 2001; 183(3):435–43. Epub 2001/
01/03. JID000924 [pii]. doi: 10.1086/318080 PMID: 11133375
39. Mejias MP, Ghersi G, Craig PO, Panek CA, Bentancor LV, Baschkier A, et al. Immunization with a chi-
mera consisting of the B subunit of Shiga toxin type 2 and brucella lumazine synthase confers total pro-
tection against Shiga toxins in mice. J Immunol. 2013; 191(5):2403–11. doi: 10.4049/jimmunol.1300999
PMID: 23918978
40. Mejias MP, Cabrera G, Fernandez-Brando RJ, Baschkier A, Ghersi G, Abrey-Recalde MJ, et al. Protec-
tion of mice against Shiga toxin 2 (Stx2)-associated damage by maternal immunization with a Brucella
lumazine synthase-Stx2 B subunit chimera. Infect Immun. 2014; 82(4):1491–9. Epub 2014/01/15.
IAI.00027-14 [pii].PubMed Central PMCID: PMC3993387. doi: 10.1128/IAI.00027-14 PMID: 24421050
Calves Immune Response after Vaccination with Escherichia coli O157:H7 Antigens
PLOS ONE | DOI:10.1371/journal.pone.0169422 January 3, 2017 13 / 15
41. Pistone Creydt VP, Miyakawa MF, Martin F, Zotta E, Silberstein C, Ibarra C. The Shiga toxin 2 B subunit
inhibits net fluid absorption in human colon and elicits fluid accumulation in rat colon loops. Brazilian
Journal of Medical and Biological Research. 2004; 37(6):799–808. Epub 2004/07/21. S0100-
879X2004000600004 [pii]. PMID: 15264022
42. Matthews L, Reeve R, Gally DL, Low JC, Woolhouse ME, McAteer SP, et al. Predicting the public health
benefit of vaccinating cattle against Escherichia coli O157. Proc Natl Acad Sci U S A. 2013; 110
(40):16265–70. PubMed Central PMCID: PMC3791763. doi: 10.1073/pnas.1304978110 PMID:
24043803
43. McKee ML, O’Brien AD. Truncated enterohemorrhagic Escherichia coli (EHEC) O157:H7 intimin
(EaeA) fusion proteins promote adherence of EHEC strains to HEp-2 cells. Infect Immun. 1996; 64
(6):2225–33. PubMed Central PMCID: PMC174060. PMID: 8675331
44. Gansheroff LJ, Wachtel MR, O’Brien AD. Decreased adherence of enterohemorrhagic Escherichia coli
to HEp-2 cells in the presence of antibodies that recognize the C-terminal region of intimin. Infect
Immun. 1999; 67(12):6409–17. PubMed Central PMCID: PMC97049. PMID: 10569757
45. Carvalho HM, Teel LD, Kokai-Kun JF, O’Brien AD. Antibody against the carboxyl terminus of intimin
alpha reduces enteropathogenic Escherichia coli adherence to tissue culture cells and subsequent
induction of actin polymerization. Infect Immun. 2005; 73(4):2541–6. PubMed Central PMCID:
PMC1087450. doi: 10.1128/IAI.73.4.2541-2546.2005 PMID: 15784601
46. Girard F, Batisson I, Frankel GM, Harel J, Fairbrother JM. Interaction of enteropathogenic and Shiga
toxin-producing Escherichia coli and porcine intestinal mucosa: role of intimin and Tir in adherence.
Infect Immun. 2005; 73(9):6005–16. Epub 2005/08/23. 73/9/6005 [pii].PubMed Central PMCID:
PMC1231093. doi: 10.1128/IAI.73.9.6005-6016.2005 PMID: 16113321
47. Martinez MB, Taddei CR, Ruiz-Tagle A, Trabulsi LR, Giron JA. Antibody response of children with
enteropathogenic Escherichia coli infection to the bundle-forming pilus and locus of enterocyte efface-
ment-encoded virulence determinants. J Infect Dis. 1999; 179(1):269–74. Epub 1998/12/08.
JID980365 [pii]. doi: 10.1086/314549 PMID: 9841853
48. Li Y, Frey E, Mackenzie AM, Finlay BB. Human response to Escherichia coli O157:H7 infection: anti-
bodies to secreted virulence factors. Infect Immun. 2000; 68(9):5090–5. Epub 2000/08/19. PubMed
Central PMCID: PMC101746. PMID: 10948130
49. Agin TS, Zhu C, Johnson LA, Thate TE, Yang Z, Boedeker EC. Protection against hemorrhagic colitis in
an animal model by oral immunization with isogeneic rabbit enteropathogenic Escherichia coli attenu-
ated by truncating intimin. Infect Immun. 2005; 73(10):6608–19. Epub 2005/09/24. 73/10/6608 [pii].
PubMed Central PMCID: PMC1230981. doi: 10.1128/IAI.73.10.6608-6619.2005 PMID: 16177337
50. Dean-Nystrom EA, Gansheroff LJ, Mills M, Moon HW, O’Brien AD. Vaccination of pregnant dams with
intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection. Infect Immun. 2002; 70
(5):2414–8. Epub 2002/04/16. PubMed Central PMCID: PMC127944. doi: 10.1128/IAI.70.5.2414-
2418.2002 PMID: 11953378
51. Cataldi A, Yevsa T, Vilte DA, Schulze K, Castro-Parodi M, Larzabal M, et al. Efficient immune
responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination
using the TLR2/6 agonist MALP-2 as adjuvant. Vaccine. 2008; 26(44):5662–7. Epub 2008/08/05.
S0264-410X(08)00970-5 [pii]. doi: 10.1016/j.vaccine.2008.07.027 PMID: 18675866
52. Joris MA, Vanrompay D, Verstraete K, De Reu K, De Zutter L, Cox E. Use of antibody responses
against locus of enterocyte effacement (LEE)-encoded antigens to monitor enterohemorrhagic Escheri-
chia coli infections on cattle farms. Applied and environmental microbiology. 2013; 79(12):3677–83.
PubMed Central PMCID: PMC3675955. doi: 10.1128/AEM.01029-13 PMID: 23563950
53. Asper DJ, Karmali MA, Townsend H, Rogan D, Potter AA. Serological response of Shiga toxin-produc-
ing Escherichia coli type III secreted proteins in sera from vaccinated rabbits, naturally infected cattle,
and humans. Clin Vaccine Immunol. 2011; 18(7):1052–7. PubMed Central PMCID: PMCPMC3147311.
doi: 10.1128/CVI.00068-11 PMID: 21593239
54. Warawa J, Finlay BB, Kenny B. Type III secretion-dependent hemolytic activity of enteropathogenic
Escherichia coli. Infect Immun. 1999; 67(10):5538–40. Epub 1999/09/25. PubMed Central PMCID:
PMC96921. PMID: 10496946
55. Ochoa TJ, Noguera-Obenza M, Ebel F, Guzman CA, Gomez HF, Cleary TG. Lactoferrin impairs type III
secretory system function in enteropathogenic Escherichia coli. Infect Immun. 2003; 71(9):5149–55.
Epub 2003/08/23. PubMed Central PMCID: PMC187368. doi: 10.1128/IAI.71.9.5149-5155.2003 PMID:
12933858
56. Knappstein S, Ide T, Schmidt MA, Heusipp G. Alpha 1-antitrypsin binds to and interferes with functional-
ity of EspB from atypical and typical enteropathogenic Escherichia coli strains. Infect Immun. 2004; 72
(8):4344–50. PubMed Central PMCID: PMC470586. doi: 10.1128/IAI.72.8.4344-4350.2004 PMID:
15271889
Calves Immune Response after Vaccination with Escherichia coli O157:H7 Antigens
PLOS ONE | DOI:10.1371/journal.pone.0169422 January 3, 2017 14 / 15
57. Takahara H, Nakamura Y, Yamamoto K, Sinohara H. Comparative studies on the serum levels of
alpha-1-antitrypsin and alpha-macroglobulin in several mammals. The Tohoku journal of experimental
medicine. 1983; 139(3):265–70. PMID: 6190264
58. Kudva IT, Griffin RW, Krastins B, Sarracino DA, Calderwood SB, John M. Proteins other than the locus
of enterocyte effacement-encoded proteins contribute to Escherichia coli O157:H7 adherence to bovine
rectoanal junction stratified squamous epithelial cells. BMC Microbiol. 2012; 12:103. Epub 2012/06/14.
1471-2180-12-103 [pii].PubMed Central PMCID: PMC3420319. doi: 10.1186/1471-2180-12-103 PMID:
22691138
59. Laplagne DA, Zylberman V, Ainciart N, Steward MW, Sciutto E, Fossati CA, et al. Engineering of a poly-
meric bacterial protein as a scaffold for the multiple display of peptides. Proteins. 2004; 57(4):820–8.
doi: 10.1002/prot.20248 PMID: 15390265
60. Kitova EN, Daneshfar R, Marcato P, Mulvey GL, Armstrong G, Klassen JS. Stability of the homopenta-
meric B subunits of shiga toxins 1 and 2 in solution and the gas phase as revealed by nanoelectrospray
fourier transform ion cyclotron resonance mass spectrometry. Journal of the American Society for Mass
Spectrometry. 2005; 16(12):1957–68. Epub 2005/10/26. S1044-0305(05)00672-0 [pii]. doi: 10.1016/j.
jasms.2005.07.016 PMID: 16242954
61. Craig PO, Berguer PM, Ainciart N, Zylberman V, Thomas MG, Martinez Tosar LJ, et al. Multiple display
of a protein domain on a bacterial polymeric scaffold. Proteins. 2005; 61(4):1089–100. doi: 10.1002/
prot.20635 PMID: 16193482
62. Fragoso G, Esquivel-Guadarrama F, Santana MA, Bobes RJ, Hernandez B, Cervantes J, et al. Heterol-
ogous prime-boost oral immunization with GK-1 peptide from Taenia crassiceps cysticerci induces pro-
tective immunity. Clin Vaccine Immunol. 2011; 18(7):1067–76. PubMed Central PMCID:
PMCPMC3147315. doi: 10.1128/CVI.05030-11 PMID: 21593234
63. Alvarez P, Zylberman V, Ghersi G, Boado L, Palacios C, Goldbaum F, et al. Tandem repeats of the
extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric car-
rier molecule induce protection in mice. Vaccine. 2013; 31(5):806–12. doi: 10.1016/j.vaccine.2012.11.
072 PMID: 23246552
64. Frohlich J, Baljer G, Menge C. Maternally and naturally acquired antibodies to Shiga toxins in a cohort
of calves shedding Shiga-toxigenic Escherichia coli. Applied and environmental microbiology. 2009; 75
(11):3695–704. PubMed Central PMCID: PMCPMC2687278. doi: 10.1128/AEM.02869-08 PMID:
19363081
65. Miyazawa H, Bannai H, Yanase T, Morita C, Satoh S, Sugiyama J, et al. A reverse-sandwich enzyme-
linked immunosorbent assay for verocytotoxin 1 and 2 antibodies in human and bovine sera. Clin Diagn
Lab Immunol. 1999; 6(5):701–4. PubMed Central PMCID: PMCPMC95758. PMID: 10473521
66. Pirro F, Wieler LH, Failing K, Bauerfeind R, Baljer G. Neutralizing antibodies against Shiga-like toxins
from Escherichia coli in colostra and sera of cattle. Vet Microbiol. 1995; 43(2–3):131–41. PMID:
7740752
67. Creydt VP, Silberstein C, Zotta E, Ibarra C. Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit
on human renal tubular epithelial cells. Microbes Infect. 2006; 8(2):410–9. Epub 2005/10/26. S1286-
4579(05)00271-6 [pii]. doi: 10.1016/j.micinf.2005.07.005 PMID: 16242986
68. Rosas G, Fragoso G, Ainciart N, Esquivel-Guadarrama F, Santana A, Bobes RJ, et al. Brucella spp.
lumazine synthase: a novel adjuvant and antigen delivery system to effectively induce oral immunity.
Microbes Infect. 2006; 8(5):1277–86. doi: 10.1016/j.micinf.2005.12.006 PMID: 16697684
69. Berguer PM, Mundinano J, Piazzon I, Goldbaum FA. A polymeric bacterial protein activates dendritic
cells via TLR4. J Immunol. 2006; 176(4):2366–72. PMID: 16455994
Calves Immune Response after Vaccination with Escherichia coli O157:H7 Antigens
PLOS ONE | DOI:10.1371/journal.pone.0169422 January 3, 2017 15 / 15
